SARS vaccine development

While there have been only isolated cases of SARS since the 2003/2004 epidemic, it is likely that we will see future outbreaks. As a result, a number of laboratories are working on strategies for a SARS vaccine. One promising approach is being reported by Jan ter Meulen and colleagues.

The researchers developed a strategy called passive immunization, in which combinations of antibodies against the SARS virus are given to individuals at risk at the time of a possible new outbreak. Passive immunization strategies have been shown to curb outbreaks of hepatitis A virus and to prevent infection with varicella-zoster virus, and such antibody prophylaxis may be an effective means of controlling a future SARS outbreak.

To be effective, it is important that an antibody-based vaccine offers sufficient breadth of protection against all relevant strains of the SARS virus and prevents the selection of escape variants in the patient. In their study, the researchers present the characteristics of a combination of two human monoclonal antibodies that seem to have the desired characteristics in cell-culture experiments in the laboratory.

###

PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

Citation: ter Meulen J, van den Brink EN, Poon LLM, Marissen WE, Leung CSW, et al. (2006) Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med 3(7): e237.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE
VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030237

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-07-meulen.pdf

CONTACT:
Jan ter Meulen
Crucell Holland B.V.
Antibody Discovery
Archimedesweg 4
Leiden, 2301 CA Netherlands
+31715248716
J.termeulen@crucell.com

About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org


Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.

 

 

When you get to the end of your rope, tie a knot and hang on.
-- Franklin D. Roosevelt